Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

3.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.

El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Br J Cancer. 2010 Jan 5;102(1):134-43. doi: 10.1038/sj.bjc.6605448. Epub 2009 Nov 17.

4.

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV.

Gynecol Oncol. 2010 Jan;116(1):15-20. doi: 10.1016/j.ygyno.2009.09.025. Epub 2009 Oct 18.

5.

Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer.

Alektiar KM, Makker V, Abu-Rustum NR, Soslow RA, Chi DS, Barakat RR, Aghajanian CA.

Gynecol Oncol. 2009 Jan;112(1):142-5. doi: 10.1016/j.ygyno.2008.10.006. Epub 2008 Nov 20.

6.

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S.

Int J Gynaecol Obstet. 2008 Aug;102(2):128-31. doi: 10.1016/j.ijgo.2008.04.008. Epub 2008 Jun 16.

PMID:
18555254
7.

Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.

Olver IN.

Future Oncol. 2008 Feb;4(1):125-31. doi: 10.2217/14796694.4.1.125. Review.

PMID:
18241007
8.

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF; Gynecologic Oncology Group..

Gynecol Oncol. 2008 Jan;108(1):3-9. Epub 2007 Oct 18.

9.

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.

Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, Falchetti M, Fontana P, Grigolato PG, Pecorelli S.

Int J Gynecol Cancer. 2008 Jan-Feb;18(1):14-21. Epub 2007 Apr 19.

PMID:
17451461
10.

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-902.

PMID:
17009989
11.

The management of serous papillary uterine cancer.

Schwartz PE.

Curr Opin Oncol. 2006 Sep;18(5):494-9. Review.

PMID:
16894299
12.

Use of trastuzumab in the treatment of metastatic endometrial cancer.

Jewell E, Secord AA, Brotherton T, Berchuck A.

Int J Gynecol Cancer. 2006 May-Jun;16(3):1370-3.

PMID:
16803532
13.

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B.

Br J Cancer. 2006 Jan 30;94(2):259-67.

14.

Rare uterine cancers.

Acharya S, Hensley ML, Montag AC, Fleming GF.

Lancet Oncol. 2005 Dec;6(12):961-71. Review. Erratum in: Lancet Oncol. 2006 Feb;7(2):105.

PMID:
16321764
15.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N.

N Engl J Med. 2005 Oct 20;353(16):1673-84.

16.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team..

N Engl J Med. 2005 Oct 20;353(16):1659-72.

17.

Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.

Hamilton CA, Liou WS, Osann K, Berman ML, Husain A, Teng NN, Kapp DS, Chan JK.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):839-44.

PMID:
16199314
18.

Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.

Díaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE.

Gynecol Oncol. 2006 Jan;100(1):139-44. Epub 2005 Sep 22.

PMID:
16182348
19.

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.

Cancer. 2005 Oct 1;104(7):1391-7.

20.

Uterine papillary serous carcinoma: what have we learned over the past quarter century?

Goff BA.

Gynecol Oncol. 2005 Sep;98(3):341-3. No abstract available.

PMID:
16111527

Supplemental Content

Support Center